Posted: 13 June 2025
Telix Pharmaceuticals Limited announced that its next-generation PSMA-PET imaging agent for prostate cancer, Gozellix® (kit for the preparation of gallium-68 (68Ga) gozetotide injection), had become commercially available nationwide in the United States (U.S.).
Kevin Richardson, Chief Executive Officer, Precision Medicine, Telix, stated, “We were pleased that Gozellix, our next-generation prostate cancer imaging product, was available coast-to-coast across the United States. Telix was committed to innovation in PSMA imaging, and Gozellix was a result of this focus. It delivered a new level of flexibility in distribution, production, and scheduling, along with the high standard of service and reliability that customers had come to expect from Telix.”
Gozellix was made available through Telix’s comprehensive network of distribution partners, including Cardinal Health, Inc., PharmaLogic Holdings Corp., Jubilant Radiopharma, and RLS Radiopharmacies.
In recent years, PSMA-PET imaging had become established as the standard of care for staging and identifying biochemical recurrence of prostate cancer. However, only a relatively small fraction of the 3.4 million men living with prostate cancer in the U.S. had benefited from this technology, partly due to access and availability challenges. Telix had applied for reimbursement for Gozellix for Medicare-eligible patients in the hospital outpatient setting.
Gozellix’s enhanced formulation, with an extended “hot” shelf-life of up to six hours, offered a greater level of patient access and convenience through an extended transportation distance and clinical administration window. Telix estimated that up to 20% of PET cameras in the U.S. were beyond the reach of currently available PSMA-PET imaging agents due to distribution efficiency constraints. By overcoming this limitation, Gozellix could improve access for prostate cancer patients, regardless of where they lived, with greater scheduling flexibility for clinicians and their patients.
For more information, click here.
